Cellectis Logo.png
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
27 mai 2024 16h30 HE | Cellectis Inc.
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
24 mai 2024 08h00 HE | Genelux Corporation
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
IN8bioLogo.jpg
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
24 mai 2024 08h00 HE | IN8bio, Inc
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
LIFT-BioSciences_full_logo-x1200.jpg
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting
24 mai 2024 02h00 HE | LIfT BioSciences
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting London, 24 May 2024 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly...
IN8bioLogo.jpg
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
23 mai 2024 17h00 HE | IN8bio, Inc
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
23andMe_Logo_grey.png
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
23 mai 2024 16h05 HE | 23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
23 mai 2024 16h01 HE | Genelux Corporation
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
Tourmaline_logo.jpg
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
23 mai 2024 07h10 HE | Tourmaline Bio, Inc.
Sandeep Kulkarni, CEO of Tourmaline Bio, is expected to participate in the Jefferies Global Healthcare Conference in New York on June 9, 2024
NEW ATAI-Logo_Primary.png
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
23 mai 2024 07h00 HE | atai Life Sciences
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
Amphista_Horiz_Logo_RGB_1500px.png
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium
23 mai 2024 07h00 HE | Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium First presentation of a novel mechanism of...